Bibliotecas PUC-SP - Busca Integrada

Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches

Por Clint T. Allen, Paul E. Clavijo, Carter Van Waes, Zhong Chen
Publicado no Cancers (2015-12-01)

Antigen processing and presentation in cancer immunotherapy

Por Maxwell Y Lee, Cem Sievers, Clint T Allen, Jun W Jeon
Publicado no Journal for ImmunoTherapy of Cancer (2020-10-01)

Determining if T cell antigens are naturally processed and presented on HLA class I molecules

Por Jay Friedman, Sreenivasulu Gunti, Maxwell Lee, Ke Bai, Christian Hinrichs, Clint T. Allen
Publicado no BMC Immunology (2022-02-01)

Trismus and voice change after starting tuberculosis treatment

Por Joseph M. Rocco, Dima A. Hammoud, Clint T. Allen, Frances Galindo, Elizabeth Laidlaw, Irini Sereti
Publicado no IDCases (2021-01-01)

ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck c...

Por Wenda Ye, Sreenivasulu Gunti, Clint T. Allen, Youji Hong, Paul E. Clavijo, Carter Van Waes, Nicole C. Schmitt
Publicado no OncoImmunology (2020-01-01)

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis

Por Maxwell Y. Lee, Simon Metenou, Douglas E. Brough, Helen Sabzevari, Ke Bai, Caroline Jochems, Jeffrey Schlom, Clint T. Allen
Publicado no npj Vaccines (2021-06-01)

Risk of recurrence after neoadjuvant chemotherapy and transoral robotic surgery in patients with oropharynx cancer that avoid adjuvant radiation

Por Alisha R. Pershad, Punam G. Thakkar, Joseph F. Goodman, Arjun Joshi, Seth M. Steinberg, Clint T. Allen, Charalampos S. Floudas
Publicado no Cancer Medicine (2024-04-01)

Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer

Por Roy Xiao, Clint T. Allen, Linda Tran, Priya Patel, So-Jin Park, Zhong Chen, Carter Van Waes, Nicole C. Schmitt
Publicado no OncoImmunology (2018-09-01)

HPV32‐related Heck’s disease in a chronic graft‐versus‐host disease patient with long‐term successful KTP laser treatment: A rare case report

Por Joe Truong Nguyen, Clint T. Allen, Joshua T. Dodge, Koenraad Van Doorslaer, Alison A. McBride, Steven Z. Pavletic, Jacqueline W. Mays
Publicado no Clinical Case Reports (2021-05-01)

Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

Por Jay Friedman, Megan Morisada, Lillian Sun, Ellen C. Moore, Michelle Padget, James W. Hodge, Jeffrey Schlom, Sofia R. Gameiro, Clint T. Allen
Publicado no Journal for ImmunoTherapy of Cancer (2018-06-01)

WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy

Por Lillian Sun, Ellen Moore, Rose Berman, Paul E. Clavijo, Anthony Saleh, Zhong Chen, Carter Van Waes, John Davies, Jay Friedman, Clint T. Allen
Publicado no OncoImmunology (2018-10-01)

Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence

Por Diana C. Lopez, Diana C. Lopez, Kellsye P. Fabian, Kellsye P. Fabian, Michelle R. Padget, Michelle R. Padget, Yvette L. Robbins, Joshua T. Kowalczyk, Joshua T. Kowalczyk, Joshua T. Kowalczyk, Wiem Lassoued, Wiem Lassoued, Danielle M. Pastor, Danielle M. Pastor, Clint T. Allen, Clint T. Allen, Clint T. Allen, Gary L. Gallia, Gary L. Gallia, James L. Gulley, James L. Gulley, James W. Hodge, James W. Hodge, Nyall R. London, Nyall R. London, Nyall R. London
Publicado no Frontiers in Oncology (2024-04-01)

PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation

Por Megan Morisada, Paul E. Clavijo, Ellen Moore, Lillian Sun, Michael Chamberlin, Carter Van Waes, James W. Hodge, James B. Mitchell, Jay Friedman, Clint T. Allen
Publicado no OncoImmunology (2018-03-01)

Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms

Por Ellen C. Moore, Lillian Sun, Paul E. Clavijo, Jay Friedman, Joe B. Harford, Anthony D. Saleh, Carter Van Waes, Esther H. Chang, Clint T. Allen
Publicado no OncoImmunology (2018-07-01)

Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials

Por Ryuhei Okada, Aki Furusawa, Daniel W. Vermeer, Fuyuki Inagaki, Hiroaki Wakiyama, Takuya Kato, Tadanobu Nagaya, Peter L. Choyke, William C. Spanos, Clint T. Allen, Hisataka Kobayashi
Publicado no EBioMedicine (2021-05-01)

Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes

Por Cem Sievers, Yvette Robbins, Ke Bai, Xinping Yang, Paul E. Clavijo, Jay Friedman, Andrew Sinkoe, Scott M. Norberg, Christian Hinrichs, Carter Van Waes, Clint T. Allen
Publicado no Communications Biology (2021-12-01)

Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies

Por James W Hodge, Michelle R Padget, Kellsye P Fabian, Joshua T Kowalczyk, Diana C Lopez, Austin TK Hoke, Clint T Allen, Mario Hermsen, Nyall R London
Publicado no Journal for ImmunoTherapy of Cancer (2022-12-01)

Cure of syngeneic carcinomas with targeted IL-12 through obligate reprogramming of lymphoid and myeloid immunity

Por Youji Hong, Yvette Robbins, Xinping Yang, Wojciech K. Mydlarz, Anastasia Sowers, James B. Mitchell, James L. Gulley, Jeffrey Schlom, Sofia R. Gameiro, Cem Sievers, Clint T. Allen
Publicado no JCI Insight (2022-03-01)

Combined Inhibition of IAPs and WEE1 Enhances TNFα- and Radiation-Induced Cell Death in Head and Neck Squamous Carcinoma

Por Tiffany Toni, Ramya Viswanathan, Yvette Robbins, Sreenivasulu Gunti, Xinping Yang, Angel Huynh, Hui Cheng, Anastasia L. Sowers, James B. Mitchell, Clint T. Allen, Ethan L. Morgan, Carter Van Waes
Publicado no Cancers (2023-02-01)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

Por Jeffrey Schlom, James W Hodge, Clint T. Allen, Shahrooz Rabizadeh, Patrick Soon-Shiong, John H. Lee, Renee N. Donahue, Kristen Solocinski, Michelle R Padget, Kellsye P Fabian, Yvette Robbins
Publicado no Journal for ImmunoTherapy of Cancer (2020-05-01)